NCT01189500View on ClinicalTrials.gov

Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Pharmacokinetics
Interventions
DRUG

Tamoxifen

Period 1-Tamoxifen 40mg on study day 1.

DRUG

Tamoxifen and Desvenlafaxine Succinate Sustained Release

Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.

Trial Locations (2)

33126

Pfizer Investigational Site, Miami

33134

Pfizer Investigational Site, Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY